Tag:
Pfizer
Latest Headlines
Latest Headlines
Pfizer rejects UK for European HQ
Citing an unwieldy bureaucracy, Pfizer has opted against putting its European headquarters in the UK, opting instead to scatter the jobs that will be created throughout other EU countries. The decision was contained in a new report that harshly criticizes the country's bureaucracy for losing hundreds of millions of pounds in new development due to its slow response times.
- here's the report on Pfizer's decision from the Guardian
Pfizer pulls the plug on indiplon pact
Shares of Neurocrine took another drubbing early today as investors digested the news that Pfizer is pulling out of its co-development pact for the sleep drug indiplon due to regulatory delays. Shares of Neurocrine lost more than a third of their value overnight. Neurocrine regains full control of indiplon, and Pfizer has agreed to support the program for another 180 days to ensure a "smooth transition."
Neurocrine stunned the market with its announcement in mid-May that the FDA …
DEALS: Deals Table headline
Schering, Celera ink $365M deal
GE Healthcare to buy Biacore International
GE Healthcare is offering $436 million for Sweden's Biacore International, which provides protein interaction analysis to biopharma companies. Pfizer Health, which owns 41 percent of the company, has approved the deal along with a majority of other shareholders. The buyout offers shareholders a 35 percent premium. Biacore has about 300 workers around the globe.
- read this AP report for more on the buyout
Editor's Corner
China has a lot riding on the ongoing court showdown over Viagra. While it's clear that many of the country's drug makers would like to continue turning out cheap copycats, the fledgling drug development industry needs a clear signal that intellectual property rights will be protected. Every week, we see new evidence of the growing role that China plays in manufacturing and testing …
Chinese companies dispute patent ruling
A group of 13 Chinese drug companies are appealing a ruling that upholds Pfizer's patent on Viagra. This dispute considered crucial to determining the country's position on counterfeit drugs and the global system of intellectual property rights that developers rely on to safeguard markets.
- read this Wall Street Journal report for more (sub. req.)
FDA concerns raise doubts on indiplon
Analysts are raising the prospect that new FDA questions concerning Neurocrine's lead drug candidate--the sleep drug indiplon--may force the company to choose between launching expensive new trials or abandoning the drug. The agency's concerns have centered on Neurocrine's request to approve a 15 milligram dose of the drug when the majority of its data is based on the results from higher doses. The FDA has already issued a non-approvable letter for the higher doses, which caused …
Pfizer gains rights to Bayer compounds
Pfizer has gained the worldwide rights to a class of compounds being developed by Bayer to treat diabetes and obesity. The compounds are DGAT-1 inhibitors which modify lipid metabolism. The lead compound of the group--BAY 74-4113--is currently in Phase I trials. Bayer gains an up-front payment, milestones and royalties, but the exact terms of the deal were not released.
"This licensing agreement with Pfizer validates the quality of our expertise in research," says Dr. Gunnar …
ADA meeting sees new data on diabetes drugs
The annual meeting of the American Diabetes Association set the stage for new data backing experimental drugs for the disease. Merck presented several studies that supported Januvia for Type 2 diabetes, with data that showed the drug lowered blood sugar without triggering significant side effects. Januvia is a DPP-4 inhibitor and its approval would mark a new class of drugs for diabetes. Pfizer also presented data for its inhaled form of insulin, Exubera. And Novartis is expected to make …
ALSO NOTED: Bidders line up for Pfizer division; Aspreva gains orphan status; and much more...
> The New York Times is reporting that Pfizer has received a series of bids toping $14 billion for its OTC drugs division. Johnson & Johnson, GSK and Reckitt Benckiser are in the lineup of interested suitors. Report
> Aspreva and Roche have received orphan drug status for CellCept, an experimental therapy for pemphigus vulgaris. CellCept is currently in Phase III. …
